- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02614651
AUgmented REality for the Visually Impaired - Part 1 (AUREVI 1)
Prospective Pilot Study on the Quantitative Evaluation of Vision Parameters Needed by Virtual Reality Goggle Displays for Subjects With Concentric Visual Field Constriction. AUgmented REality for the Visually Impaired - Part 1
The main objective of this study is to quantify vision parameters in subjects with concentric visual field constriction, and this in relation to the display on virtual reality goggles. More specifically:
- The maximum brightness value for visual comfort (THRESHOLD_MAX)
- The minimum value of the perceptible light contrast in low light perceptible (THRESHOLD_MIN)
- The speed of light change adaptation in the range [THRESHOLD_MAX-THRESHOLD_MIN] and [THRESHOLD_MIN-THRESHOLD_MAX].
Study Overview
Status
Conditions
Detailed Description
Secondary objectives are to:
A. Quantifying the device parameters "RV glasses + camera" depending on visual acuity and the visual field of each subject:
- Optimal extent of the visual field provided by the device "RV glasses + camera".
B. Measuring the effectiveness of different image processing algorithms used in the development of the software part of this technical assist device:
- Capture and display HDR images (High Dynamic Range)
- Color adjustment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Nîmes Cedex 09, France, 30029
- CHRU de Nîmes - Hôpital Universitaire Carémea
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The subject is suffering from retinitis pigmentosa or glaucoma with concentric visual field constriction and presents with:
- An acuity in the better eye superior or equal to 1/10 in near vision,
- A binocular field of between 1° and 30°,
- A good central fixation, absence of central scotoma,
- Motor capability for using a computer keyboard with one hand.
Exclusion Criteria:
- The patient is participating in another study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, or under guardianship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- Subjects with (or evolving toward) a multiple sensory disability, or one including cognitive disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: The study population
The study population consists of subjects with a concentric constriction of the visual field (retinitis pigmentosa, glaucoma) whose motor capacity allows the use of a computer keyboard with one hand. Subjects are recruited on a voluntary basis, from information disseminated to professionals in the rehabilitation of functional low vision and patient associations, in the Ophthalmology Service of the University Hospital of Nimes and within the ARAMAV Institute. Intervention: Find visual comfort threshold related to light intensity Intervention: Find the size of the visual field Intervention: Effectiveness of brightness control Intervention: Performance of color correction Intervention: Vuzix Wrap 1200DX virtural reality glasses |
In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes. The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the "space" bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally.
For these tests, the subject is seated at a table, 1.5m from a wall.
It features a computer keyboard.
It projects an image on the wall, using to a video projector.
An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness. The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object. During this session, the investigators try to assess the performance for the color vision correction (saturation and hue). The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions.
The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX.
In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model.
The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The maximum brightness value for visual comfort (THRESHOLD_MAX)
Time Frame: 0 to 6 months
|
0 to 6 months
|
|
The minimum value of the perceptible light contrast in low light perceptible (THRESHOLD_MIN)
Time Frame: 0 to 6 months
|
0 to 6 months
|
|
The speed of light change adaptation within a pre-specified range (getting dimmer)
Time Frame: 0 to 6 months
|
The pre-specified range goes from THRESHOLD_MAX down to THRESHOLD_MIN.
|
0 to 6 months
|
The speed of light change adaptation within a pre-specified range (getting brighter)
Time Frame: 0 to 6 months
|
The pre-specified range goes from THRESHOLD_MIN up to THRESHOLD_MAX.
|
0 to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Optimal range (in degrees) of the visual field provided by the device "RV glasses + camera"
Time Frame: 0 to 6 months
|
0 to 6 months
|
Response time in seconds
Time Frame: 0 to 6 months
|
0 to 6 months
|
Number of correct responses
Time Frame: 0 to 6 months
|
0 to 6 months
|
Collaborators and Investigators
Investigators
- Study Director: Isabelle Marc, PhD, Laboratoire LGI2P, Ecole Nationale Supérieure des Mines
- Principal Investigator: Luc Jeanjean, MD, Centre Hospitalier Universitaire de Nîmes
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LOCAL/2015/IMGD-01
- 2016-A00099-42 (Other Identifier: RCB number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
University of California, San FranciscoUniversity of Colorado, Denver; University of Maryland; Zhongshan Ophthalmic... and other collaboratorsCompletedPrimary Open Angle Glaucoma | Glaucoma | Neovascular Glaucoma | Secondary GlaucomaUnited States, China, India, Mexico